Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 3Neoplasms 2Lymphoma 2Lung Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Nose Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Esthesioneuroblastoma, Olfactory 1Esophageal Neoplasms 1

Interventions

Cyclophosphamide 30Vincristine 22Rituximab 19Etoposide 19Prednisone 18Filgrastim 16Doxorubicin 16Cytarabine 16Methotrexate 15Radiotherapy 14Peripheral Blood Stem Cell Transplantation 13merphos 11Leucovorin 11blinatumomab 10N,N-dicyclohexyl-isoborneol-10-sulfonamide 10Mercaptopurine 10Dexamethasone 10azathiopurine 9Specimen Handling 9Methylprednisolone 9Calcium Dobesilate 9Biopsy 9dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8Cyclosporine 8prednylidene 7pegaspargase 7fludarabine phosphate 7deltacortene 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Burkitt Lymphoma × Positron-Emission Tomography × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡